

# Adam D Cohen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7631029/adam-d-cohen-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64  
papers

4,252  
citations

28  
h-index

65  
g-index

68  
ext. papers

5,694  
ext. citations

8  
avg, IF

5.38  
L-index

#	Paper	IF	Citations
64	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 32	7	3
63	CAR T cell therapy for multiple myeloma: What have we learned?. <i>Leukemia</i> , <b>2022</b> ,	10.7	1
62	Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. <i>Blood</i> , <b>2021</b> , 138, 2746-2746	2.2	1
61	Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2101754	2.2	
60	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 851-855	4.5	0
59	Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8005-8005	2.2	12
58	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. <i>Cancer</i> , <b>2021</b> , 127, 4198-4212	6.4	23
57	Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	15
56	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , <b>2021</b> , 398, 314-324	40	118
55	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6580-6590	12.9	1
54	CRISPR-engineered T cells in patients with refractory cancer. <i>Science</i> , <b>2020</b> , 367,	33.3	44 <sup>8</sup>
53	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 22-25	2.2	44
52	Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8536-8536	2.2	20
51	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1541-1554	12.9	35
50	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 207-221	21.7	281
49	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma <b>2020</b> , 8,		13
48	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 106	7	20

47	Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3969-3978	12.9	6
46	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. <i>Blood Advances</i> , <b>2019</b> , 3, 2487-2490	7.8	23
45	Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1633-1646	12.5	13
44	Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 37	7	126
43	Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. <i>American Journal of Hematology</i> , <b>2019</b> , 94, S28-S33	7.1	26
42	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4451-4463	15.9	48
41	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 2210-2221	15.9	312
40	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1863-1863	2.2	13
39	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 658-669	12.5	8
38	Myeloma: next generation immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , <b>2019</b> , 2019, 266-272	3.1	17
37	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 2812-2815	7.8	61
36	Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2018</b> , 4, e174519	13.4	124
35	A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. <i>Kidney International</i> , <b>2018</b> , 94, 199-205	9.9	56
34	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 1886-1886	2.2	14
33	CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, e6-e15	7.1	37
32	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	90
31	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1641-1653	21.7	141
30	Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2551	8.4	56

29	The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. <i>OncolImmunology</i> , <b>2017</b> , 6, e1339853	7.2	43
28	NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. <i>OncolImmunology</i> , <b>2017</b> , 6, e1330235	7.2	32
27	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. <i>Blood</i> , <b>2017</b> , 130, 741-741	2.2	30
26	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2698-704	2.2	677
25	Improved Survival in AL Amyloidosis: A Population-Based Study on 1,430 Patients Diagnosed in Sweden 1995-2013. <i>Blood</i> , <b>2016</b> , 128, 4448-4448	2.2	10
24	Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. <i>Blood</i> , <b>2016</b> , 128, 4548-4548	2.2	7
23	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. <i>Blood</i> , <b>2016</b> , 128, 5702-5702	2.2	23
22	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 974-974	2.2	27
21	Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. <i>Blood</i> , <b>2015</b> , 126, 2284-90	2.2	174
20	Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. <i>Lancet Haematology</i> , <b>2015</b> , 2, e408-16	14.6	95
19	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 356-69	2	6
18	GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 320-31	12.5	114
17	Combination immune therapies to enhance anti-tumor responses by NK cells. <i>Frontiers in Immunology</i> , <b>2013</b> , 4, 481	8.4	57
16	Enhanced responses to tumor immunization following total body irradiation are time-dependent. <i>PLoS ONE</i> , <b>2013</b> , 8, e82496	3.7	10
15	Assessing CD137 (4-1BB) As a Therapeutic Target in B-Cell Neoplasms,. <i>Blood</i> , <b>2011</b> , 118, 3735-3735	2.2	
14	Results of Radiation Therapy for Primary Extranodal Lymphoma of the Head and Neck: A Report of Case Series. <i>Blood</i> , <b>2011</b> , 118, 4761-4761	2.2	
13	Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. <i>PLoS ONE</i> , <b>2010</b> , 5, e10436	3.7	194
12	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. <i>Journal of Experimental Medicine</i> , <b>2009</b> , 206, 1103-16	16.6	174

11	Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. <i>British Journal of Haematology</i> , <b>2007</b> , 139, 224-33	4.5	96
10	High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 5113-5113	2.2	
9	DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. <i>Journal of Immunology</i> , <b>2006</b> , 177, 4159-67	5.3	15
8	Adjuvant Dexamethasone (D) □ Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).. <i>Blood</i> , <b>2005</b> , 106, 1163-1163	2.2	2
7	The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 3481-3481	2.2	1
6	Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.. <i>Blood</i> , <b>2005</b> , 106, 1156-1156	2.2	
5	DNA vaccines for melanoma. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , <b>2005</b> , 22, 761-8		1
4	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , <b>2004</b> , 104, 304-304	2.2	
3	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.. <i>Blood</i> , <b>2004</b> , 104, 3057-3057	2.2	
2	An update on hepatic arterial infusion chemotherapy for colorectal cancer. <i>Oncologist</i> , <b>2003</b> , 8, 553-66	5.7	92
1	Modulating the immune response to genetic immunization. <i>FASEB Journal</i> , <b>1998</b> , 12, 1611-1626	0.9	146